As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, ...
Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...
5hon MSN
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...
President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
Pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations, reductions that are expected to produce billions in savings for taxpayers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback